Bertozzi
Carolyn Bertozzi’s Valora Therapeutics Launches with $30M Seed Round to Develop Sugar-Based Immunotherapies
Carolyn Bertozzi, Valora Therapeutics, immunotherapy, sugar-based treatments, biotech startup, $30M seed round
Revolutionary Protein Degraders Integrated into Antibody-Drug Conjugates: Carolyn Bertozzi and Versant Launch New Biotech with $94 Million Funding
Carolyn Bertozzi, Versant Ventures, Firefly Bio, Protein degraders, Antibody-drug conjugates (ADCs), Degrader-Antibody Conjugates (DACs), $94 million funding